NCMGF News Alert Newcrest Mining Ltd (NCMGF) 11.1300 02/15/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Newcrest Mining Ltd (NCMGF) 11.1300 $NCMGF

Just Another Bear Market Rally In Gold
Ben Lockhart - at Seeking Alpha - Mon Feb 02, 2:25AM CST

ABX: 12.14 (+0.01), GOLD: 78.29 (-0.31), NEM: 24.78 (+0.27), TLT: 128.19 (-1.33), SPY: 209.78 (+0.86), GDXJ: 27.00 (+0.38), AEM: 32.61 (+0.10), EGO: 4.94 (+0.10), GLD: 117.98 (+0.64), FNV: 52.32 (+0.01), SLW: 22.76 (+0.34), RGLD: 71.46 (+0.50), GDX: 21.26 (+0.11), GG: 23.54 (+0.23)

Newcrest Mining sets higher output targets but Lihir project remains a drag
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 2:45PM CST


Aussie Toe Cutters Girding Companies For The Long Haul
The Gold Report - Seeking Alpha - Tue Dec 30, 9:34AM CST
In Australia, when companies want to cut costs, they hire what are known as "toe cutters." These managers root out inefficiency and drive profitability. Vincent Pisani, senior resources analyst with Shaw Stockbroking in Sydney, Australia,...
TSLA: 203.77 (+0.89), BHP: 51.19 (+2.38), RIO: 49.37 (+2.22)

Insiders Are Not Buying These Gold Mining Stocks
Prudent Finances - at Seeking Alpha - Fri Nov 07, 1:22PM CST

EGO: 4.94 (+0.10), AEM: 32.61 (+0.10), ABX: 12.14 (+0.01), GOLD: 78.29 (-0.31), FNV: 52.32 (+0.01), SLW: 22.76 (+0.34), NEM: 24.78 (+0.27), RGLD: 71.46 (+0.50), GDX: 21.26 (+0.11), GG: 23.54 (+0.23)

Investors Turn Against Gold After Price Decline
Markit - Seeking Alpha - Wed Nov 05, 8:10AM CST
With developments mirroring the recent plight of high cost oil producers in the face of sinking oil prices, we analyse investment flows and sentiment towards gold as the precious metal price points towards $1000 per fine ounce. QE ends but now big...
ABX: 12.14 (+0.01), KGC: 2.81 (-0.17), GLD: 117.98 (+0.64), GFI: 4.83 (-0.21), GDX: 21.26 (+0.11), SBGL: 10.85 (+0.12)

Wall Street Breakfast: European Shares Slip After EU Commission Cuts Forecasts
Wall Street Breakfast - Seeking Alpha - Tue Nov 04, 5:32AM CST
Economy European shares gave up early gains and turned negative after the European Commission revised down its growth forecasts and predicted more of the low inflation and high unemployment that plagues the bloc. "There is no single and...
BX: 37.40 (+0.49), DIS: 104.17 (+0.59), GOOG: 549.01 (+6.08), PBR: 6.98 (+0.44), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), JPM: 59.67 (+0.10), IBM: 160.40 (+1.88), S: 5.23 (+0.08), XCO: 2.52 (+0.20), UIS: 23.37 (+0.27), GOOGL: 551.16 (+5.15), FL: 53.96 (-0.13), HMC: 32.87 (+0.14), AAPL: 127.08 (+0.62), SYK: 94.51 (+1.14)

Today In SA PRO: Monday, November 3
SA PRO Top Ideas - at Seeking Alpha - Tue Nov 04, 4:00AM CST
Top Idea: Newcrest Mining by Da Shi Research: Short / Mid-Cap / Gold Mining / Value / Overvaluation / Strained Balance Sheet Outstanding Performance Awards Seeking Alpha is awarding contributors for great calls playing out. Read more about...
ZQK: 2.26 (+0.05), RENT: 58.90 (+0.39), CHKP: 80.33 (+2.13), IPGP: 87.26 (+0.07)

Newcrest Is Overvalued And A Great Gold Short
Da Shi Research - at Seeking Alpha - Tue Nov 04, 4:00AM CST





Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading